Desperate patients get early access to experimental muscle cell therapy
NCT ID NCT04661293
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program offers expanded access to an experimental treatment using a patient's own muscle cells. It is for people with serious or life-threatening conditions who have no other options. Doctors can request the treatment for eligible patients, but it is not yet proven to work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- autologous muscle derived cells (AMDCs)
- What this could lead to
- If successful, this program could provide a treatment option for patients with serious muscle-related diseases who have no other alternatives.
- What could go wrong
- This is an early expanded access program, not a full clinical trial. The treatment is still investigational, and benefits are not guaranteed. Risks are not fully known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new related studies are added.
By submitting, you agree to our Terms of use
Contacts and locations
Locations
-
Cook MyoSite, Inc.
Pittsburgh, Pennsylvania, 15238, United States